We are live on !
Find out more
BVF Inc Portfolio holdings
AUM
$3.91B
Turnover
15.22%
1-Year Est. Return
304.52%
This Fund
S&P 500
This Quarter Est. Return
+11.17%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.93%
10 Year Est. Return
+28,184.7%
AUM
$469M
AUM Growth
+$65.3M
(+16%)
Cap. Flow
+$30.3M
Cap. Flow % of AUM
Cap. Flow %
6.45%
Top 10 Holdings %
Top 10 Hldgs %
67.79%
Holding
39
New
8
Increased
4
Reduced
7
Closed
5
Avg Time Held
1.4
years
Top 10 Avg Time Held
1.4
years
Top 20 Avg Time Held
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ionis Pharmaceuticals
IONS
|
+$27.4M |
| 2 |
INFI
Infinity Pharmaceuticals, Inc.
INFI
|
+$24.2M |
| 3 |
Crescent Biopharma
CBIO
|
+$16.9M |
| 4 |
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
|
+$8.47M |
| 5 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$6.24M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ironwood Pharmaceuticals
IRWD
|
+$19.2M |
| 2 |
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
|
+$11.4M |
| 3 |
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
|
+$8.82M |
| 4 |
QLT Inc
QLTI
|
+$5.3M |
| 5 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$2.05M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.75% |
| 2 | Miscellaneous | 9.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
DELISTED
Blueprint Medicines
BPMC
| $58.6M | 12.49% |
2,895,251
+255,000
| +10% | +$4.63M |
2015 Q2
4 quarters
|
|
2
Cytokinetics
CYTK
$7.68B
| $47.3M | 10.09% |
4,989,218
+648,489
| +15% | +$5.32M |
2013 Q2
12 quarters
|
|
3
DELISTED
ChemoCentryx, Inc.
CCXI
| $36.7M | 7.83% |
8,182,052
| – | – |
2013 Q2
12 quarters
|
|
|
CNCE
4
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $30.9M | 6.59% |
2,755,318
| – | – |
2014 Q3
7 quarters
|
|
5
DELISTED
Array Biopharma Inc
ARRY
| $29.4M | 6.27% |
8,260,897
+410,686
| +5% | +$1.34M |
2013 Q2
12 quarters
|
|
|
FWP
6
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
| $25.9M | 5.51% |
203,516
-2,382
| -1% | -$321K |
2014 Q4
6 quarters
|
|
|
7
Ionis Pharmaceuticals
IONS
$5.15B
| $19.8M | 4.22% |
+850,000
| New | +$27.4M |
2016 Q2
0 quarters
|
|
|
8
Crescent Biopharma
CBIO
$507M
| $17.8M | 3.79% |
+24,474
| New | +$16.9M |
2016 Q2
0 quarters
|
|
|
CASC
9
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $17.7M | 3.78% |
3,133,228
| – | – |
2013 Q2
12 quarters
|
|
|
OMED
10
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $16.5M | 3.51% |
1,339,336
| – | – |
2013 Q3
11 quarters
|
|
|
TBRA
11
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
| $15.7M | 3.35% |
1,253,401
| – | – |
2013 Q3
11 quarters
|
|
|
CTIC
12
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $15.2M | 3.24% |
4,479,694
| – | – |
2015 Q3
3 quarters
|
|
|
ARQL
13
DELISTED
Arqule Inc
ARQL
| $14.2M | 3.02% |
7,450,128
-443,196
| -6% | -$751K |
2013 Q2
12 quarters
|
|
14
Xenon Pharmaceuticals
XENE
$3.92B
| $10.5M | 2.24% |
1,775,572
| – | – |
2014 Q4
6 quarters
|
|
15
DELISTED
Alpine Immune Sciences Inc
ALPN
| $8.86M | 1.89% |
481,611
+94,925
| +25% | +$1.68M |
2015 Q4
2 quarters
|
|
|
VTAE
16
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
| $8.21M | 1.75% |
761,079
-1,327,935
| -64% | -$11.4M |
2014 Q3
7 quarters
|
|
|
PRTK
17
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $8M | 1.7% |
+575,000
| New | +$8.47M |
2016 Q2
0 quarters
|
|
|
INFI
18
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $6.9M | 1.47% |
+5,184,600
| New | +$24.2M |
2016 Q2
0 quarters
|
|
19
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $6.33M | 1.35% |
8,223
| – | – |
2014 Q4
6 quarters
|
|
20
CytomX Therapeutics
CTMX
$432M
| $6.19M | 1.32% |
606,138
| – | – |
2015 Q4
2 quarters
|
|
|
KDNY
21
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $5.81M | 1.24% |
+102,721
| New | +$6.24M |
2016 Q2
0 quarters
|
|
22
MacroGenics
MGNX
$149M
| $5.4M | 1.15% |
+200,000
| New | +$4.51M |
2016 Q2
0 quarters
|
|
23
DELISTED
Esperion Therapeutics
ESPR
| $4.93M | 1.05% |
499,142
-107,659
| -18% | -$1.78M |
2016 Q1
1 quarter
|
|
24
Filana Therapeutics
FLNA
$24.8M
| $4.71M | 1% |
307,130
| – | – |
2015 Q3
3 quarters
|
|
|
25
DELISTED
QLT Inc
QLTI
| $3.2M | 0.68% |
2,255,476
-3,446,133
| -60% | -$5.3M |
2013 Q2
12 quarters
|
|
Similar funds
LFCM
AC
BVF Inc's Q2 2016 Portfolio in Review
As of Q2 2016, BVF Inc held 39 positions worth $469M, up 16% from $404M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
BVF Inc deployed $30.3M of net new capital in Q2 2016, opening 8 new positions and adding to 4 existing holdings. Its largest new stake was Ionis Pharmaceuticals: 850,000 shares worth $19.8M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 88% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was VITAE PHARMACEUTICALS INC COMMON STOCK, an estimated $11.4M trimmed.
- BVF Inc's largest Q2 2016 buy was Ionis Pharmaceuticals: 850,000 shares worth $19.8M.
- BVF Inc added most to Cytokinetics in Q2 2016, an estimated $5.32M increase.
- BVF Inc's biggest Q2 2016 reduction was VITAE PHARMACEUTICALS INC COMMON STOCK, cutting an estimated $11.4M.
- BVF Inc fully exited Ironwood Pharmaceuticals in Q2 2016, selling an estimated $19.2M.
- BVF Inc's ten largest holdings make up 68% of its $469M portfolio in Q2 2016.
- BVF Inc opened 8 new positions and closed 5 in Q2 2016.
- BVF Inc's portfolio value rose 16% quarter-over-quarter to $469M.
Based on BVF Inc's 13F filing for Q2 2016, filed 15 Aug 2016.